1. Market Research
  2. > Healthcare Market Trends
NPS+ Renal Cell Carcinoma (EU5)

NPS+ Renal Cell Carcinoma (EU5)

  • February 2016
  • ID: 3673820

Summary

Table of Contents

Compare 8 major RCC brands. Learn which one scores 6 times higher than any other?

FirstView’s NPS+ Renal Cell Carcinoma report compares brand loyalty for 8 major RCC treatments—information you can use to improve your brand’s health, and boost your market share.

Based on your brand’s net promoter score (NPS), the report shows you how likely doctors are to recommend your brand, which of your competitors they recommend, and which promotional messages drive those recommendations. Plus you’ll learn how doctors really perceive your brand.

Based on your brand’s net promoter score (NPS), the report shows you how likely doctors are to recommend your brand, which of your competitors they recommend, and which promotional messages drive those recommendations. Plus you’ll learn how doctors really perceive your brand.

Intuitive, easy to use KPIs highlight areas for improvement and make your next steps crystal clear.

Interested in the US market? Click here to see the US Edition.

Find out How Doctors View Renal Cell Carcinoma Drug Brands


Afinitor (everolimus; Novartis): Does Afinitor’s route of administration or benefit/risk profile drive more recommendations?
Avastin (bevacizumab; Roche): How important is cost to Avastin Promoters?
Inlyta (axitinib; Pfizer): Which leading brand’s Detractors are most likely to promote Inlyta?

Opdivo (nivolumab; Bristol-Myers Squibb): Oncologists associate Opdivo with a novel mechanism of action. Does that drive the most recommendations?
Proleukin (aldesleukin; Prometheus): What does Proleukin’s brand DNA reveal about why Detractors won’t recommend it?
Sutent (sunitinib malate; Pfizer): More than 90% of Sutent Promoters also promote one brand. Which one?
Torisel (temsirolimus; Pfizer): Which EU5 countries’ oncologists had the most positive comments about Torisel?
Votrient (pazopanib; Novartis): Is slowing disease progression or reducing relapses a more effective brand message among Votrient Promoters?


Top Takeaways


NPS scores show a clear market leader: Only three surveyed brands have a positive NPS, but the leading brand’s score is nearly six times that of its nearest competitor.
Satisfaction moderate, lower than in US: Fewer than 65% of oncologists surveyed are satisfied with available RCC drugs. In the US, the figure is over 70%.
Exclusivity is relatively high: More than 20% of oncologists surveyed promote one brand exclusively.
Cost is a low priority: For all but one surveyed brand, clinical attributes drive recommendations far more than cost concerns.
One brand has the potential for massive market share gain: Twice as much as any other surveyed brand if it can turn its Detractors into Promoters.
Two brands are the top choices among Promoters: Which two brands do Promoters of nearly all surveyed brands recommend more than any others.
Brand switching is common: Brand Promoters recommend 4 other brands on average. Detractors tend to promote most of the other surveyed brands (though not in large numbers).
Oncologists are optimistic about new treatments: Low NPS and market share notwithstanding, oncologists from every EU5 country praised one recently-approved brand for innovation.


Explore Important Brand Loyalty Issues

NPS+ Renal Cell Carcinoma (EU5) explores key issues affecting brand loyalty for RCC drug manufacturers.

You’ll learn:

How satisfied the RCC market is.
How loyal doctors are to your brand.
How many other brands your Promoters recommended.
Which other brands your Promoters and Detractors recommend.
How much market share your brand has among Promoters and Detractors.
How much market share you stand to gain by converting Detractors into Promoters.
Which messages Promoters, Passives and Detractors associate with your brand.
Your brand DNA: what doctors really think of your brand—in their own words.


A Report Based on Expert Knowledge

We surveyed 150 Medical Oncologists from the EU5 (France, Italy, Germany, Spain, UK), chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between January 4th and 8th, 2015.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:<

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:

Detractors are those who answer 0 – 6.
Passives are those who answer 7 – 8.
Promoters are those who answer 9 - 10.

How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.


What is FirstView NPS+?
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Healthcare Fraud Detection Market by Type, Application, Component, Delivery, End user - Global Forecast to 2022

Healthcare Fraud Detection Market: Global Forecast until 2022

  • $ 6328
  • Industry report
  • January 2018
  • by MarketsandMarkets

Global healthcare fraud detection market projected to grow at a CAGR of 28.9%The healthcare fraud detection market is expected to reach USD 2,242.7 million by 2022 from USD 631.0 million in 2017, at a ...

Hysteroscopy Instruments Market by Product, Resectoscope, Usability, Application, End User - Global Forecast to 2022

Hysteroscopy Instruments Market: Global Forecast until 2022

  • $ 5650
  • Industry report
  • October 2017
  • by MarketsandMarkets

“Global hysteroscopy instruments market projected to grow at a CAGR of 7.8%”The hysteroscopy instruments market is expected to reach USD 1.89 billion by 2022 from USD 1.30 billion in 2017, at a CAGR ...

Behavioral/Mental Health Software Market by Component, Delivery, Functionality, End User And Region - Global Forecast to 2022

Behavioral/Mental Health Software Market: Global Forecast until 2022

  • $ 5650
  • Industry report
  • October 2017
  • by MarketsandMarkets

“Global behavioral health software market projected to grow at a CAGR of 14.8%”The behavioral health software market is expected to reach USD 2.31 billion by 2022 from USD 1.15 billion in 2017, at ...


ref:plp2016

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.